ArticleCancer medicine2022

Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet-Uro 19BEYOND study.

Giandomenico Roviello et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.